Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Alergia e Inmunología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 3
ClinicalTrials.gov
Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures
INTERVENTIONAL
Inicio: 1 de jun de 2008
ID: NCT00678587
Aún no recluta
Fase 3
ClinicalTrials.gov
Prospective, Randomised, DBPC Clinical Trial to Evaluate the Efficacy and Safety of Polymerized and Mannan Conjugated Allergen Extract of Dermatophagoides for the Treatment of Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
INTERVENTIONAL
Inicio: 1 de nov de 2023
ID: NCT05641272
Terminado
Fase 2
ClinicalTrials.gov
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
INTERVENTIONAL
Inicio: 18 de ago de 2021
ID: NCT04900038
Terminado
Fase 3
ClinicalTrials.gov
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIIM Study
INTERVENTIONAL
Inicio: 21 de oct de 2019
ID: NCT04044690
Completado
ClinicalTrials.gov
An Observational Multi-Centre Field Study to Assess Symptom Scores and Allergy Medication Usage in Subjects With a History of Grass-Induced Rhinoconjunctivitis
OBSERVATIONAL
Inicio: 1 de abr de 2014
ID: NCT02075138
Completado
Fase 1
ClinicalTrials.gov
A Phase I Study to Evaluate the Safety, Tolerance and Pharmacokinetics of the Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers
INTERVENTIONAL
Inicio: 16 de dic de 2017
ID: NCT03388216
Completado
ClinicalTrials.gov
Long-term Persistence of Immunoglobulin G Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Vulnerable Neighbourhood in Buenos Aires, Argentina
OBSERVATIONAL
Inicio: 2 de dic de 2020
ID: NCT04673279
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents
INTERVENTIONAL
Inicio: 28 de sept de 2016
ID: NCT02879305
Reclutando
Fase 3
ClinicalTrials.gov
An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
INTERVENTIONAL
Inicio: 6 de ago de 2021
ID: NCT04910269
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00504075
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)
INTERVENTIONAL
Inicio: 7 de ene de 2016
ID: NCT02555371
Completado
Fase 3
ClinicalTrials.gov
A Two Week Randomized, Double Blind Placebo Controlled, Parallel Group Study of GW685698X Aqueous Nasal Spray 100mcg and 50mcg QD in Pediatric Subjects With Perennial Allergic Rhinitis
INTERVENTIONAL
Inicio: 1 de feb de 2005
ID: NCT00108914
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)
INTERVENTIONAL
Inicio: 8 de may de 2025
ID: NCT06935357
Terminado
Fase 2
ClinicalTrials.gov
An Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety of Subcutaneous 240mg QGE031 Given Every 4 Weeks for 52 Weeks in Allergic Asthma Patients Who Completed Study CQGE031B2201
INTERVENTIONAL
Inicio: 27 de mar de 2014
ID: NCT02075008
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
INTERVENTIONAL
Inicio: 18 de nov de 2024
ID: NCT06692738
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Dose Range Finding Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy
INTERVENTIONAL
Inicio: 31 de oct de 2012
ID: NCT01679951
Completado
Fase 2
ClinicalTrials.gov
A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects
INTERVENTIONAL
Inicio: 1 de jun de 2005
ID: NCT00110305
Completado
ClinicalTrials.gov
Prospective Observational Study of Site-Specific Incident and Prevalent Cases of Cancer in People Living With HIV/AIDS- in Latin America
OBSERVATIONAL
Inicio: 17 de ene de 2020
ID: NCT04089488
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
INTERVENTIONAL
Inicio: 27 de nov de 2024
ID: NCT06627647
Completado
ClinicalTrials.gov
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
OBSERVATIONAL
Inicio: 1 de may de 2012
ID: NCT01582763
Anterior
1
2
3
4
...
434
Siguiente
Filtros